Evidence map›Paper›PMID 39228168›Full record

ArticleBritish journal of clinical pharmacology2024

Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients.

Tom G Jacobs, Hylke Waalewijn, Lily Houlden, Pauline D J Bollen, Annet Nanduudu, Esether Nambi, Haseena Cassim, Abbas Lugemwa, Shafic Makumbi, Lara N Monkiewicz and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical and Epidemiological Profile of Dolutegravir Use and Antiretroviral Resistance in Honduras.Health education & behavior : the official publication of the Society for Public Health Education · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Tom G JacobsDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-5738-5528
Hylke WaalewijnDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Lily HouldenMedical Research Council Clinical Trials Unit, University College London, London, UK.
Pauline D J BollenDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Annet NanduuduJoint Clinical Research Centre, Kampala, Uganda.
Esether NambiJoint Clinical Research Centre, Kampala, Uganda.
Haseena CassimPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Abbas LugemwaJoint Clinical Research Centre, Mbarara, Uganda.
Shafic MakumbiJoint Clinical Research Centre, Mbarara, Uganda.
Lara N MonkiewiczMedical Research Council Clinical Trials Unit, University College London, London, UK.
Clare ShakeshaftMedical Research Council Clinical Trials Unit, University College London, London, UK.
Alasdair BamfordMedical Research Council Clinical Trials Unit, University College London, London, UK.
Moherndran ArcharyDurban International Clinical Research Site, Durban, South Africa.ORCID https://orcid.org/0000-0003-3082-9234
Godfrey MusuroUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Ennie ChidzivaUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Hilda A MujuruUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Mutsa Bwakura-DangarembiziUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Chishala ChabalaDepartment of Paediatrics and Child Health, School of Medicine, University of Zambia, Lusaka, Zambia.
Anna TurkovaMedical Research Council Clinical Trials Unit, University College London, London, UK.
Di M GibbMedical Research Council Clinical Trials Unit, University College London, London, UK.
Mark F CottonFamily Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa.
Rob AarnoutseDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
David M BurgerDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-7279-2818
Angela ColbersDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

European and Developing Countries Clinical Trials Partnership TRIA2015-1078European & Developing Countries Clinical Trials Partnership (EDCTP) TRIA2015-1078Gilead SciencesJanssen PharmaceuticaMedical Research Council MC_UU_00004/03ViiV Healthcare
6 · The paper itself

Abstract

Dolutegravir (DTG) is primarily metabolized by uridine diphosphate glucuronosyltransferases, forming the pharmacologically inactive DTG glucuronide (DTG-gluc). We described the dolutegravir metabolic ratio (DTG-MR; DTG-gluc AUC

Indexed as

Drug InteractionsGlucuronidesHeterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsOxazinesPiperazinesPyridonesRifampinAdolescentAge FactorsArea Under CurveChildChild, PreschoolDolutegravirFemaleDolutegravirGlucuronidesHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesReverse Transcriptase InhibitorsRifampinchildrendolutegravirdrug–drug interactionglucuronidationHIVpharmacokineticsUGT1A1

Identifiers

PMID39228168
PMCPMC7616883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.